Skip to main content

Table 3 Anti-c-Met therapies currently under investigation in clinical trials for breast cancer [11]

From: The clinical and functional significance of c-Met in breast cancer: a review


Target/mechanism of action identifier

Tivantinib (ARQ197)

c-Met/non-ATP kinase inhibitor

NCT 01575522

Cabozantinib (XL184)

c-Met and VEGFR, along with RET, KIT, AXL/kinase inhibitor

NCT 01738438

Foretinib (XL880)

c-Met and VEGFR, along with KIT, Flt-3, PDGFR, Tie-2/kinase inhibitor

NCT 01147484

MetMab (onartuzumab)

c-Met/anti-c-Met antibody

NCT 01186991

  1. PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor.